Growth inhibition of a prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide.
The effects of the ornithine decarboxylase suicide substrate, difluoromethylornithine (DFMO), and of cyclophosphamide, individually and in combination, on the growth of the R3327MAT-Lu prostate derived tumor were determined. DFMO decreased the growth rate and resulted in a 75% reduction in DNA content compared to the control group. Cyclophosphamide produced a greater inhibition of growth and resulted in a 96% reduction in DNA content relative to the control. DFMO in combination with cyclophosphamide provided no greater inhibition of tumor growth than that of cyclophosphamide as a single agent. Further, in the schedule used in this experimental protocol the toxicity to the host of the drug combination was additive.
D000818:Animals; D002460:Cell Line; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004247:DNA / Q000096:biosynthesis; D004359:Drug Therapy, Combination; D000518:Eflornithine; D008297:Male; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D009952:Ornithine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009955:Ornithine Decarboxylase / Q000378:metabolism; D065108:Ornithine Decarboxylase Inhibitors; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D051381:Rats
D065108:Ornithine Decarboxylase Inhibitors; D003520:Cyclophosphamide; D004247:DNA; D009952:Ornithine; D009955:Ornithine Decarboxylase; D000518:Eflornithine